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Introduction: Antibiotics used to treat post-stroke infections have differing antimicrobial
and anti-inflammatory effects. Our aim was to investigate whether antibiotic class was
associated with outcome after post-stroke infection.
Methods: We analyzed pooled individual participant data from the Virtual International
Stroke Trials Archive (VISTA)-Acute. Patients with ischemic stroke and with an infection
treated with systemic antibiotic therapy during the first 2 weeks after stroke onset
were eligible. Antibiotics were grouped into eight classes, according to antimicrobial
mechanism and prevalence. The primary analysis investigated whether antibiotic class
for any infection, or for pneumonia, was independently associated with a shift in 90 day
modified Rankin Scale (mRS) using ordinal logistic regression.
Results: 2,708 patients were eligible (median age [IQR] = 74 [65 to 80] y; 51% female;
median [IQR] NIHSS score= 15 [11 to 19]). Pneumonia occurred in 35%. Treatment with
macrolides (5% of any infections; 9% of pneumonias) was independently associated with
more favorable mRS distribution for any infection [OR (95% CI)= 0.59 (0.42 to 0.83), p=
0.004] and for pneumonia [OR (95% CI) = 0.46 (0.29 to 0.73), p = 0.001]. Unfavorable
mRS distribution was independently associated with treatment of any infection either with
carbapenems, cephalosporins or monobactams [OR (95% CI) = 1.62 (1.33 to 1.97), p
< 0.001], penicillin plus β-lactamase inhibitors [OR (95% CI) = 1.26 (1.03 to 1.54), p =
0.025] or with aminoglycosides [OR (95% CI) = 1.73 (1.22 to 2.46), p = 0.002].
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Conclusion: This retrospective study has several limitations including effect modification
and confounding by indication. Macrolides may have favorable immune-modulatory
effects in stroke-associated infections. Prospective evaluation of the impact of antibiotic
class on treatment of post-stroke infections is warranted.
Keywords: stroke, acute, post-stroke infections, post-stroke pneumonia, antibiotics, prognosis
INTRODUCTION
Infections frequently complicate stroke, occurring in up
to 30% of patients, and increase the likelihood of death
and unfavorable outcomes in survivors (1–3). Whilst
antibiotics are the mainstay of treatment, the microbiological
etiology of common infections complicating stroke, such as
pneumonia or urinary tract infection, are poorly characterized.
Further, there are no antibiotic treatment trials of infections
complicating stroke. The effectiveness of different antibiotic
classes is therefore uncertain, there is a lack of evidence
to inform antibiotic guidelines (e.g., for pneumonia
complicating stroke) and empirical antibiotic treatment is
variable (4, 5).
Inflammatory and immune responses play a central role in
the pathophysiology of stroke and associated clinical outcomes
(6). Post-stroke infections exacerbate deleterious inflammatory
and immune responses, which may impact further on adverse
outcomes (7). Antibiotics used to treat post-stroke infections
can modulate the pathophysiology of experimental stroke
independent of their anti-microbial effects, by modulating
inflammatory or excitotoxic pathways (8–14). Randomized trials
of prophylactic antibiotics in acute stroke have failed to improve
clinical outcomes or prevent pneumonia (3, 5, 15–17), and
had varying effects in preventing urinary tract infections. This
has raised questions about the potential effectiveness of some
antibiotic classes commonly used for post-stroke infections,
particularly pneumonia (18).
Taken together, these data suggest that choice of antibiotic
class for post-stroke infections could have important implications
for clinical outcomes. We therefore hypothesized that
antibiotic class influences outcome after stroke relating
to spectrum of antimicrobial coverage and to other (e.g.,
inflammatory) mechanisms independent of antimicrobial
effects. The aim of this study was to investigate whether class of
antibiotic used to treat clinically diagnosed pneumonia or any
infection in the first 2 weeks after stroke was associated with
clinical outcomes.
PATIENTS AND METHODS
We undertook a retrospective pooled analysis of individual
participant data from the Virtual International Stroke Trials
Archive (VISTA)-Acute (www.virtualtrialsarchives.org/vista).
The study protocol was approved by the VISTA-Acute Steering
Committee. Dedicated ethical approval was not required
as anonymized historical patient data were being used.
The VISTA-Acute repository was screened by the VISTA
coordinator for eligible acute ischemic stroke randomized
controlled trials (RCTs) meeting the following study-level
criteria: (i) Adverse Event (AE) and Serious Adverse Event
(SAE) data recorded during the first 2 weeks after enrolment
which included post-stroke infections, including both type of
infection and name of antibiotic therapy; (ii) 90 day clinical
outcomes: modified Rankin Scale (mRS), National Institutes
of Health Stroke Scale (NIHSS) and Barthel Index (BI);
(iii) core demographic variables (including age, sex, country
where randomized, year of study, vascular risk profile and
smoking history) and clinical variables (baseline NIHSS,
baseline mRS pre-stroke, concurrent medications, baseline
glucose concentration). For the eligible RCTs identified,
individual participant data for trial participants with an infection
recorded and treated within the first 2 weeks after stroke onset
were anonymized and extracted. Individual participant SAE
and AE data were reviewed by a single researcher (CJS) to
classify infection sub-type and categorize systemic antibiotic
treatment by class, blinded to the baseline characteristics and
clinical outcomes.
Infection Category
Categorization of the infections into sub-types was based
on review of the information recorded in the reported SAEs
and AEs, and was therefore necessarily both pragmatic
and also reflective of usual clinical practice. Infections
were categorized as follows: (i) Pneumonia (including
description or coding of pneumonia, aspiration pneumonia,
inhalation pneumonia, chest infection, lung consolidation,
bronchopulmonary infection, bronchial infection); (ii)
Tracheobronchitis (including acute bronchitis, acute
exacerbation of bronchitis, acute tracheobronchitis, upper
respiratory tract infection, exacerbation of chronic airways
disease/obstructive pulmonary disease or asthma); (iii)
Urogenital infections (including urinary tract infection,
pyelonephritis, cystitis, prostatitis, vaginal infection); (iv) Other
defined infections (skin and soft tissue, dental, joint, gastro-
intestinal, meningitis/ ventriculitis, pharyngeal/throat, and
ear) requiring systemic antibiotics. The majority of these were
self-explanatory based on reported diagnosis (e.g., aspiration
pneumonia, acute bronchopneumonia, hospital-acquired
pneumonia; acute tracheobronchitis, exacerbation of chronic
bronchitis; acute pyelonephritis, urinary tract infection) or
description (e.g., “yellow secretions, basilar crackle + scattered
rhonchi”; “infection intravenous cannula site”). A final category,
(v) Uncertain source of infection, was included for when
there was sufficient clinical suspicion of infection to initiate
systemic antibiotics but without a definite source of infection
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reported or where the site of infection could not be concluded
from the available information. Patients were excluded if
they received preventative antibiotics; had an identified
infection but received no systemic antibiotic treatment, received
treatment for an infection caused by proven or suspected
Candida spp or Mycobacterial spp. Uncertainties relating to
the site of infection or any other aspect of categorization
into sub-type were resolved by discussion with the study
microbiologist (ARJ).
Antibiotic Class
All recorded antibiotics were individually reviewed by
a single researcher (CJS). Antibiotics with systemic
(oral, via enteral tube, intravenous or intramuscular)
administration were grouped, prior to consideration of
their association with outcomes, as follows based on
mechanism of action (Table 1) and prevalence in the final
cohort: (i) lincosamides and tetracyclines; (ii) cephalosporins,
carbapenems, and monobactams; (iii) aminoglycosides;
(iv) fluoroquinolones; (v) penicillins; (vi) penicillin plus β-
lactamase inhibitor; (vii) other (sulphonamides, folic acid
inhibitors, metronidazole, nitrofurans, and glycopeptides);
(viii) macrolides.
Statistical Analyses
The exposure of interest was antibiotic class used to treat
post-stroke infection during the first 2 weeks after ischemic
stroke onset. The primary outcome measure was the 7-point
mRS score at 90 days (incorporating death as score 6).
Secondary outcomes included NIHSS and BI at 90 days. Baseline
characteristics were summarized for pooled study data. To
determine whether antibiotic class, or other prognostic variables
were associated with the primary outcome, we performed
multifactorial ordinal logistic regression to obtain an adjusted
odds ratio with 95% confidence interval (CI) for a shift in
mRS. Antibiotic class and infection subtype were each entered
into the model as categorical predictor variables, allowing us
to account for subsequent infections and multiple different
antibiotic exposures in the analysis. Other potential confounding
individual-level and study-level characteristics were also included
as independent variables and included age, sex, year, geographical
region/continent, baseline NIHSS, categorical infection subtype,
thrombolysis treatment, and prior statin treatment. We included
statins as they are independently associated with outcome after
stroke (19) and are implicated in both the risk of stroke-
associated infections and prognosis (20–23). Data restrictions
prevented direct inclusion of a trial identifier in the analyses.
In the primary analysis we investigated the independent
association between antibiotic class and 90 day mRS both for
any infection and also for pneumonia separately. Secondary
analyses of 90 day BI and NIHSS incorporated deceased
patients, and used ordinal logistic regression undertaken for any
infection and also pneumonia separately, adjusted for the same
independent variables. TA
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Sample Size
A preliminary screen of individual participant data for >30
RCTS in VISTA-Acute led us to anticipate inclusion of >2,000
participants meeting the eligibility criteria. We anticipated that
statistical power would depend critically on the distribution of
antibiotic classes used, and that of the mRS within patients
treated for infection. Analysis on the ordinal scale, assuming
the proportional odds assumption holds in eligible patients, as
it would be anticipated to do in unselected patients, would
increase power over a binary outcome analysis. For illustrative
purposes, a simple power calculation on the binary scale
indicated that a comparison of 600 patients treated with each
of two classes of antibiotics would provide 80% power to
detect an odds ratio of 1.5 from a baseline of 75% with
“good outcome.”
RESULTS
2,708 patients were eligible with a total of 3,081 infections
treated with systemic antibiotics during the first 2 weeks after
stroke onset (any infection). Pneumonia occurred in 35%,
and urogenital infections in 42% of the participants. Trials
between 1998 and 2013 were represented, which included
participating centers from Europe, Asia, Africa, Australasia
and the Americas. The baseline characteristics and clinical
outcomes for the final sample (median age [IQR] = 74 [65
to 80] y; 51% female; median [IQR] NIHSS score = 15 [11
to 19]; 90 day case fatality 26%) and the different infection
categories are presented in Table 2. The baseline characteristics
and clinical outcomes for patients receiving the different
antibiotic classes in any infection and pneumonia are presented
in Tables 3, 4.
The prevalence of the antibiotic classes in the different
infection categories is shown in Table 5. Antibiotic
dosage, duration and route of administration were not
available. Table 6 shows the frequency of prescription of
monotherapy with one antibiotic agent, or combination
treatment with >1 antibiotic agent, for the infection
categories. Combination therapy with >1 antibiotic agents
occurred most often in pneumonia, with at least two
antibiotics prescribed in 42% of cases compared with 20%
TABLE 2 | Baseline characteristics and 90 day clinical outcomes according to infection category.
Number of infections Any infection
3081
Pneumonia
958
Tracheobronchitis
170
Urogenital infection
1132
Other infection
330
Uncertain infection
491
Number of patients 2708 958 170 1132 330 490
Median (IQR) age (y) 74 (65 to 80) 74 (66 to 80) 72 (65 to 78) 74 (66 to 80) 73 (64 to 80) 73 (65 to 79)
Female sex, n (%) 1372 (51%) 387 (40%) 67 (39%) 727 (64%) 140 (42%) 225 (46%)
Median (IQR) NIHSS 15 (11 to 19) 16 (12 to 20) 13 (9 to 17) 14 (11 to 18) 14 (10 to 17) 16 (12 to 20)
Median (IQR) time to first
infection (d)
5 (3 to 9) 4 (2 to 7) 3 (2 to 7) 6 (3 to 14) 6 (3 to 21) 4 (2 to 6)
IV thrombolysis, n (%) 795 (26%) 270 (28%) 44 (26%) 282 (25%) 75 (23%) 124 (25%)
Mean (SD) pre-stroke mRS 1.2 (0.6) 1.2 (0.6) 1.1 (0.3) 1.3 (0.7) 1.3 (0.8) 1.2 (0.5)
Median (IQR) glucose
concentration (mmol/L)
6.9 (5.8 to 8.6) 7.0 (5.9 to 9.0) 6.9 (5.7 to 9.1) 6.7 (5.7 to 8.2) 6.8 (5.8 to 8.4) 7.2 (6.0 to 8.7)
Prior statin, n (%) 210 (6%) 43 (4%) 10 (6%) 97 (9%) 32 (10%) 28 (6%)
Vascular risk factors, N (%)
Previous stroke 558 (19%) 184 (20%) 35 (21%) 197 (18%) 64 (20%) 78 (17%)
Previous TIA 258 (9%) 83 (9%) 10 (6%) 96 (9%) 28 (9%) 41 (9%)
Diabetes mellitus 685 (22%) 231 (24%) 42 (25%) 218 (19%) 71 (22%) 123 (25%)
Hypertension 1994 (66%) 609 (64%) 115 (69%) 731 (66%) 213 (65%) 326 (67%)
Previous myocardial
infarction
390 (13%) 142 (15%) 16 (10%) 136 (12%) 46 (14%) 50 (10%)
Atrial fibrillation 841 (29%) 302 (33%) 43 (27%) 277 (27%) 78 (26%) 141 (31%)
Smoking status
Non-smoker 322 (10%) 94 (10%) 10 (6%) 133 (12%) 37 (11%) 48 (10%)
Smoker 495 (16%) 147 (15%) 19 (11%) 191 (17%) 63 (19%) 75 (15%)
90 day outcomes, median (IQR)
mRS 4 (3 to 6) 5 (4 to 6) 4 (2 to 5) 4 (2 to 5) 4 (2 to 6) 4 (3 to 6)
BI 25 (0 to 80) 5 (0 to 55) 55 (0 to 95) 50 (5 to 85) 30 (0 to 85) 10 (0 to 70)
NIHSS 11 (4 to 42) 17 (7 to 42) 7 (3 to 42) 8 (3 to 16) 11 (3 to 42) 13 (5 to 42)
90 day case fatality, n (%) 794 (26%) 353 (37%) 39 (23%) 157 (14%) 84 (26%) 161 (33%)
NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; TIA, transient ischemic attack; BI, Barthel Index.
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TABLE 3 | Baseline characteristics and 90 day outcomes according to antibiotic class exposure in any infection.
Lincosamides and
tetracyclines
Cephalosporins,
carbapenems and
monobactams
Aminoglycosides Fluoroquinolones Penicillins Penicillin plus
β-lactamase
inhibitors
Other* Macrolides
Number of
patients
180 815 165 930 315 873 670 142
Median (IQR)
age (y)
74 (63 to 80) 73 (65 to 80) 73 (67 to 79) 74 (66 to 80) 75 (65 to 80) 74 (65 to 80) 75 (67 to 81) 71 (62 to 79)
Female sex, n (%) 73 (41%) 363 (45%) 59 (36%) 505 (54%) 158 (50%) 385 (44%) 384 (57%) 61 (43%)
Median (IQR)
NIHSS
17 (12 to 20) 15 (11 to 19) 16 (12 to 19) 14 (11 to 19) 15 (11 to 19) 15 (11 to 19) 15 (11 to 19) 13 (9 to 18)
Median (IQR) time
to first infection (d)
4 (2 to 8) 5 (2 to 8) 6 (3 to 12) 5 (3 to 10) 7 (4 to 17) 4 (2 to 7) 6 (3 to 15) 5 (2 to 11)
IV thrombolysis, n
(%)
43 (24%) 187 (23%) 30 (18%) 267 (29%) 73 (23%) 248 (28%) 179 (27%) 36 (25%)
Mean (SD)
pre-stroke mRS
1.2 (0.7) 1.2 (0.6) 1.4 (0.8) 1.1 (0.5) 1.5 (0.9) 1.1 (0.6) 1.4 (0.8) 1.3 (0.7)
Median (IQR)
glucose (mmol/L)
7.4 (5.9 to 9.1) 6.8 (5.8 to 8.9) 7.3 (6.1 to 8.5) 6.8 (5.9 to 8.4) 6.7 (5.8 to 8.6) 7.2 (5.9 to 9.2) 6.7 (5.8 to 8.3) 6.5 (5.7 to
7.9)
Prior statin, n (%) 8 (4%) 62 (8%) 11 (7%) 66 (7%) 22 (7%) 58 (7%) 60 (9%) 4 (3%)
Vascular risk factors, n (%)
Previous stroke 33 (19%) 146 (19%) 31 (19%) 156 (17%) 50 (17%) 149 (18%) 148 (23%) 28 (20%)
Previous TIA 15 (9%) 62 (8%) 13 (8%) 77 (9%) 22 (7%) 68 (8%) 59 (9%) 9 (6%)
Diabetes
mellitus
49 (27%) 189 (23%) 42 (25%) 195 (21%) 68 (22%) 222 (25%) 155 (23%) 23 (16%)
Hypertension 108 (60%) 518 (65%) 117 (71%) 607 (66%) 195 (64%) 557 (65%) 460 (69%) 69 (49%)
Previous
myocardial
infarction
25 (14%) 98 (12%) 31 (19%) 113 (12%) 35 (11%) 104 (12%) 87 (13%) 17 (12%)
Atrial fibrillation 60 (35%) 216 (29%) 47 (30%) 243 (28%) 92 (32%) 234 (28%) 172 (28%) 34 (25%)
Smoking status
Non-smoker 23 (13%) 107 (13%) 14 (8%) 121 (13%) 39 (12%) 51 (6%) 56 (8%) 10 (7%)
Smoker 31 (17%) 153 (19%) 28 (17%) 160 (17%) 61 (19%) 105 (12%) 140 (21%) 27 (19%)
90 day outcomes, median (IQR)
mRS 5 (4 to 6) 4 (3 to 6) 5 (4 to 6) 4 (3 to 5) 4 (3 to 5) 4 (3 to 6) 4 (3 to 6) 3 (2 to 5)
BI 0 (0 to 45) 10 (0 to 65) 0 (0 to 45) 40 (0 to 85) 25 (0 to 75) 20 (0 to 75) 15 (0 to 70) 65 (0 to 95)
NIHSS 19 (8 to 42) 14 (6 to 42) 20 (8 to 42) 9 (3 to 36) 11 (4 to 42) 12 (5 to 42) 12 (4 to 42) 7.5 (3 to 42)
90 day case
fatality, n (%)
69 (39%) 271 (33%) 64 (39%) 203 (22%) 63 (20%) 264 (31%) 180 (27%) 32 (23%)
*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides, and nitrofurans.
NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; TIA, transient ischemic attack; BI, Barthel Index.
in tracheobronchitis, 21% in urogenital infections and 33% in
other infections.
In the primary analyses (Table 7, Figures 1, 2), treatment
with macrolides (5% of any infections; 9% of pneumonias)
was independently associated with more favorable mRS
distribution for any infection [OR (95% CI) = 0.59 (0.42
to 0.83), p = 0.004] and for pneumonia [OR (95% CI) =
0.46 (0.29 to 0.73), p = 0.001]. By contrast, unfavorable mRS
distribution was independently associated with treatment
of any infection with carbapenems, cephalosporins or
monobactams [35% of any infections; OR (95% CI) =
1.62 (1.33 to 1.97), p < 0.001], penicillin plus β-lactamase
inhibitor [35% of any infections; OR (95% CI) = 1.26 (1.03
to 1.54), p = 0.025] or with aminoglycosides [7% of any
infections; OR (95% CI) = 1.73 (1.22 to 2.46), p = 0.002]
(Figure 1).
In secondary analyses, treatment with macrolides for any
infection or pneumonia was also independently associated with
more favorable BI and NIHSS (Tables 8, 9, Figures 1, 2).
Treatment of any infection with carbapenems, cephalosporins
or monobactams; penicillin plus β-lactamase inhibitor or
with aminoglycosides was also independently associated with
unfavorable BI and NIHSS (Figure 1).
A sensitivity analysis of the primary and secondary
analyses included interaction terms between each antibiotic
class and baseline stroke severity using the NIHSS score.
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TABLE 4 | Baseline characteristics and 90 day outcomes according to antibiotic class exposure in pneumonia.
Lincosamides and
tetracyclines
Cephalosporins,
carbapenems, and
monobactams
Aminoglycosides Fluoroquinolones Penicillins Penicillin plus
β-lactamase
inhibitors
Other* Macrolides
Number of
patients
120 403 78 254 115 395 224 83
Median (IQR)
age (y)
75 (64 to 80) 73 (64 to 80) 72.5 (64 to 80) 75 (67 to 80) 76 (66 to 81) 75 (67 to 81) 75 (67.5 to 81) 70 (64 to 79)
Female sex, n (%) 48 (40%) 159 (39%) 24 (31%) 97 (38%) 44 (38%) 161 (41%) 93 (42%) 37 (45%)
Median (IQR)
NIHSS
17 (12 to 20) 16 (12 to 19) 16.5 (13 to 20) 16 (13 to 20) 16 (13 to 18) 16 (12 to 20) 16 (11 to 19) 14 (10 to 18)
Median (IQR) time
to first infection (d)
4 (2 to 7) 4 (2 to 7) 5 (3 to 8) 4 (2 to 7.5) 6 (3 to 15) 4 (2 to 7) 5 (3 to 9) 3.5 (1 to 7)
IV thrombolysis, n
(%)
27 (23%) 96 (24%) 13 (17%) 87 (34%) 29 (25%) 131 (33%) 65 (29%) 19 (23%)
Mean (SD)
pre-stroke mRS
1.3 (0.7) 1.2 (0.5) 1.4 (0.8) 1.1 (0.5) 1.4 (0.8) 1.2 (0.6) 1.3 (0.8) 1.2 (0.7)
Median (IQR)
glucose (mmol/L)
7.4 (6 to 9.7) 6.8 (5.7 to 8.9) 7 (5.8 to 8.4) 6.8 (5.9 to 8.9) 6.7 (5.9 to 8.6) 7.3 (5.9 to 9.8) 6.7 (5.7 to 8.3) 6.4 (5.7 to
8.2)
Prior statin, n (%) 3 (3%) 26 (6%) 3 (4%) 12 (5%) 7 (6%) 18 (5%) 13 (6%) 1 (1%)
Vascular risk factors, n (%)
Previous stroke 22 (19%) 78 (21%) 13 (18%) 43 (17%) 25 (22%) 67 (17%) 46 (21%) 18 (22%)
Previous TIA 9 (8%) 30 (8%) 9 (12%) 25 (10%) 11 (10%) 34 (9%) 12 (5%) 5 (6%)
Diabetes
mellitus
28 (23%) 96 (24%) 18 (23%) 64 (25%) 23 (20%) 106 (27%) 54 (24%) 11 (13%)
Hypertension 64 (54%) 248 (63%) 53 (68%) 169 (67%) 76 (67%) 252 (65%) 152 (68%) 37 (45%)
Previous
myocardial
infarction
19 (15%) 57 (14%) 12 (15%) 36 (14%) 19 (17%) 56 (14%) 31 (13%) 10 (12%)
Atrial fibrillation 44 (39%) 119 (32%) 22 (29%) 72 (30%) 44 (40%) 122 (33%) 69 (34%) 20 (24%)
Smoking status
Non-smoker 14 (12%) 57 (14%) 7 (9%) 33 (13%) 9 (8%) 31 (8%) 15 (7%) 6 (7%)
Smoker 21 (18%) 79 (20%) 13 (17%) 54 (21%) 23 (20%) 52 (13%) 48 (21%) 14 (17%)
90 Day outcomes, median (IQR)
mRS 5 (4 to 6) 5 (4 to 6) 5 (4 to 6) 5 (4 to 6) 4 (4 to 6) 5 (4 to 6) 5 (4 to 6) 4 (2 to 6)
BI 0 (0 to 35) 5 (0 to 50) 0 (0 to 25) 5 (0 to 45) 5 (0 to 40) 5 (0 to 55) 0 (0 to 35) 60 (0 to 95)
NIHSS 19 (8 to 42) 18 (7.5 to 42) 42 (10 to 42) 16 (7 to 42) 16 (8 to 42) 16 (7 to 42) 19 (8 to 42) 8 (3 to 42)
90 day case
fatality, n (%)
45 (38%) 151 (38%) 32 (41%) 90 (36%) 32 (28%) 144 (37%) 85 (38%) 22 (27%)
*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides, and nitrofurans.
NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; TIA, transient ischemic attack; BI, Barthel Index.
This was to examine whether any apparent association
between antibiotic class and change in outcome could be
due to an interaction with stroke severity. We did not find
evidence of any interaction between any of the antibiotic
classes and baseline stroke severity, including for macrolides
(data not shown).
Forty-five percent of infections treated with macrolides were
with macrolides alone. In the remainder, macrolides were most
frequently combined with cephalosporins, fluoroquinolones or
penicillin plus β-lactamase inhibitor. By contrast, 70% of
infections treated with penicillin plus β-lactamase inhibitor
were with monotherapy, the remainder were combined most
often with fluoroquinolones or cephalopsorins. Fifty-nine
percent of infections treated with cephalosporins were with
monotherapy, the remainder used combination treatment most
often with metronidazole, fluoroquinolones or penicillin plus
β-lactamase inhibitor.
DISCUSSION
We found that treatment with macrolides was independently
associated with a favorable clinical outcome in any infection
or pneumonia complicating stroke. Macrolides were only used
in a minority of post-stroke infections and were mainly used
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TABLE 5 | Prevalence of antibiotic classes for infection categories expressed as % of total number of antibiotic prescriptions.
Number of patients Any infection
2708
Pneumonia
958
Tracheobronchitis
170
Urogenital infection
1132
Other infection
330
Uncertain infection
490
Number of antibiotic prescriptions 5237 1862 233 1723 650 769
Antibiotic class, n (%)
Lincosamides and tetracyclines
Tetracyclines 33 (0.6%) 10 (0.5%) 9 (3.9%) 1 (<0.1%) 13 (2%) 0
Lincosamides 186 (3.6%) 124 (6.7%) 3 (1.3%) 10 (0.6%) 15 (2.3%) 34 (4.4%)
Cephalosporins, carbapenems, monobactams
Cephalosporins 986 (18.8%) 436 (23.4%) 45 (19.3%) 216 (12.5%) 125 (19.2%) 164 (21.3%)
Carbapenems 90 (1.7%) 49 (2.6%) 2 (0.9%) 13 (0.8%) 18 (2.8%) 8 (1.0%)
Monobactams 11 (0.2%) 1 (<0.1%) 0 2 (0.1%) 6 (0.9%) 2 (0.3%)
Aminoglycosides 208 (4%) 82 (4.4%) 9 (3.9%) 33 (1.9%) 56 (8.6%) 28 (3.6%)
Fluoroquinolones 1129 (21.6%) 244 (13.1%) 50 (21.5%) 651 (37.8%) 66 (10.2%) 118 (15.3%)
Penicillins 433 (8.3%) 138 (7.4%) 15 (6.4%) 164 (9.5%) 64 (9.9%) 52 (6.8%)
Penicillin plus β-lactamase inhibitors 1082 (20.7%) 456 (24.5%) 80 (34.3%) 179 (10.4%) 83 (12.8%) 284 (36.9%)
Other
Glycopeptides 184 (3.5%) 74 (4.0%) 1 (0.4%) 17 (1%) 67 (10.3%) 25 (3.3%)
Metronidazole 301 (5.7%) 151 (8.1%) 2 (0.9%) 24 (1.4%) 96 (14.8%) 28 (3.6%)
Nitrofurans 60 (1.1%) 0 0 58 (3.4%) 0 (0) 2 (0.3%)
Sulphonamides/folic acid inhibitors 372 (7.1%) 9 (0.5%) 2 (0.9%) 346 (20.1%) 8 (1.2%) 7 (0.9%)
Macrolides 162 (3.1%) 88 (4.7%) 15 (6.4%) 9 (0.5%) 33 (5.1%) 17 (2.2%)
TABLE 6 | Number of antibiotic agents prescribed for infection categories.
Number of
patients
Any infection
2708
Pneumonia
958
Tracheobronchitis
170
Urogenital infection
1132
Other infection
330
Uncertain infection
490
NUMBER OF ANTIBIOTIC AGENTS PRESCRIBED, n (%)
1 2184 (70.9%) 554 (57.8%) 136 (80.0%) 895 (79.1%) 221 (67.0%) 378 (77.0%)
2 669 (21.7%) 295 (30.8%) 30 (17.7%) 188 (16.6%) 72 (21.8%) 84 (17.1%)
3 165 (5.4%) 85 (8.9%) 2 (1.2%) 35 (3.1%) 21 (6.4%) 22 (4.5%)
4 49 (1.6%) 17 (1.8%) 2 (1.2%) 11 (1.0%) 12 (3.6%) 7 (1.4%)
5 11 (0.4%) 5 (0.5%) 0 2 (0.2%) 4 (1.2%) 0
6 3 (0.1%) 2 (0.2%) 0 1 (0.1) 0 0
as combination therapy with other antibiotics. By contrast,
treatment with cephalosporins, carbapenems or monobactams;
or penicillin plus β-lactamase inhibitors, was consistently
associated with unfavorable outcome in any infection, but
not pneumonia. These two classes were each used in the
treatment of over one third of post-stroke infections, mainly
as monotherapy. Aminoglycosides were also associated with
unfavorable outcome when used to treat any infection but
accounted for a small proportion of the antibiotic classes
used. These associations were consistently observed with
all three clinical outcome measures in the primary and
secondary analyses.
Genito-urinary infections were marginally more frequent
than pneumonia in our study. This is in keeping with
a recent study using both clinician-diagnosed and expert
panel-adjudicated diagnosis of urinary tract infection and
pneumonia (3) and estimates from meta-analysis of stroke
studies (2, 24, 25). However, pneumonia is associated with
substantial risk of death and disability compared to urinary
tract infections (2) and is regarded as the major research
and clinical priority amongst stroke-associated infections. Our
data accord with this as only pneumonia, but not other
infection sub-types, was independently associated with worse
clinical outcomes.
Our retrospective study has several limitations which
necessitate caution when interpreting the findings. First, choice
of antibiotic class will have been influenced by study- and
individual-level factors, leading to effect modification and
confounding by indication. We were unable to include a
trial-identifier in our analyses to account for non-specific
differences in study populations. Perceived severity of infection
will likely have been a determinant of choice of antibiotic
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TABLE 7 | Multifactorial ordinal logistic regression for associations with
unfavorable 90 day mRS.
Pneumonia (n = 791
patients)
Any infection (n = 2254
patients)
OR 95% CI p OR 95% CI p
Antibiotic class
Lincosamides and
tetracyclines
0.95 0.62 to 1.45 0.82 1.37 0.98 to 1.91 0.07
Cephalosporins,
carbapenems, and
monobactams
1.31 0.96 to 1.78 0.09 1.62 1.33 to 1.97 <0.001
Aminoglycosides 1.04 0.62 to 1.76 0.87 1.73 1.22 to 2.46 0.002
Fluoroquinolones 1.05 0.77 to 1.44 0.74 1.22 1.01 to 1.47 0.040
Penicillins 0.95 0.62 to 1.44 0.81 1.16 0.89 to 1.52 0.28
Penicillin plus
β-lactamase
inhibitor
0.94 0.69 to 1.28 0.68 1.26 1.03 to 1.54 0.025
Other* 1.30 0.72 to 2.35 0.38 1.48 1.21 to 1.82 <0.001
Macrolides 0.46 0.29 to 0.73 0.001 0.59 0.42 to 0.83 0.004
Sex
Female Ref Ref
Male 1.02 0.79 to 1.33 0.86 1.02 0.87 to 1.19 0.84
Increasing age (y) 1.05 1.04 to 1.06 <0.001 1.05 1.04 to 1.05 <0.001
Baseline NIHSS 1.11 1.08 to 1.15 <0.001 1.15 1.13 to 1.17 <0.001
Infection subtype
Pneumonia 1.47 1.09 to 1.97 0.011
Tracheobronchitis 0.92 0.63 to 1.36 0.69
Urogenital 0.64 0.48 to 0.85 0.002
Other 0.77 0.57 to 1.02 0.097
Uncertain 1.17 0.86 to 1.58 0.31
Treated with IV alteplase
No Ref Ref
Yes 0.95 0.70 to 1.29 0.73 0.80 0.66 to 0.96 0.016
Prior statin
No Ref Ref
Yes 1.14 0.30 to 2.16 0.69 1.14 0.83 to 1.57 0.42
Unrecorded 1.71 0.96 to 3.02 0.07 1.62 1.18 to 2.23 0.003
Smoking status
Non-smoker Ref Ref
Smoker 1.29 0.67 to 2.16 0.69 1.21 0.83 to 1.57 0.42
Unrecorded 1.15 0.49 to 2.68 0.75 1.04 0.65 to 1.67 0.88
Region
Australasia/ Africa Ref Ref
Asia 0.85 0.39 to 1.85 0.68 1.14 0.68 to 1.92 0.62
Europe 0.85 0.41 to 1.77 0.66 1.10 0.67 to 1.79 0.72
America 0.92 0.44 to 1.96 0.84 1.03 0.62 to 1.69 0.91
Increasing year of
study
0.97 0.90 to 1.04 0.41 1.00 0.96 to 1.04 0.88
*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides
and nitrofurans.
mRS, modified Rankin Scale; OR, Odds ratio; CI, Confidence Interval; NIHSS, National
Institutes of Health Stroke Scale; IV, intravenous.
class, along with availability of oral, enteral or parenteral
routes, local antibiotic policy and allergy status. Bacterial
species implicated in aspiration pneumonia have changed in
recent years as anaerobes are less frequently isolated (26).
Changing patterns of antimicrobial susceptibility may also have
influenced regional and local prescribing. Plasma C-reactive
protein was not sufficiently available for the regression analyses,
but may still have been used by treating clinicians to inform
antibiotic choice. Second, details of route, dose and duration
of treatment were not available and may also have influenced
the findings. Third, the criteria used for diagnosis of infection
were not available and will have varied between different units,
leading to under- or over-diagnosis and therefore selection bias.
There were also very limited microbiological data available,
reflected by the need for an uncertain infection category,
where infection was suspected (and antibiotics initiated) yet
a definite site was not recorded. As there are no ubiquitous,
validated criteria for diagnosing common post-stroke infections
such as pneumonia, and positive microbiological data are
infrequent (27), this reflects real-life practice. Finally, our
categorization of antibiotic class required a balance between
prevalence and mechanisms of action, to avoid over-fitting the
regression models. We were therefore unable to further sub-
divide antibiotic classes, such as creating a separate category for
carbapenems and for monobactams, or by generation of drug
(e.g., cephalopsorins).
In randomized trials of prophylactic antibiotics in acute
stroke, several classes of antibiotics commonly used for
post-stroke infections, including cephalosporins, penicillin
plus β-lactamase inhibitors and fluoroquinolones, did
not appear to prevent pneumonia complicating stroke,
even in patients selected at higher-risk (3, 5, 15–17).
This raises the possibility that some antibiotics are
not optimally effective against pneumonia complicating
stroke (18). Whilst this may have contributed to our
observations, the limitations of our study necessitate that
such hypothesis-generation requires testing in appropriately
designed studies.
Antibiotics used to treat post-stroke infections could
influence clinical outcome by three main mechanisms. First,
antimicrobial spectrum could explain differential outcomes
between antibiotic classes. Stroke-associated pneumonia
is predominantly associated with aerobic Gram-negative
bacilli (e.g., Klebsiella pneumoniae and Escherichia coli) and
Gram-positive cocci (e.g., Stapylococcus spp.) (27). Whilst
the antimicrobial spectrum of β-lactam antibiotics varies,
penicillin plus β-lactamase inhibitors and third generation
cephalosporins are broadly comparable despite differences in
coverage of Pseudomonas spp. By contrast, macrolides are mainly
active against Gram-positive organisms (e.g., Streptococcus
pneumoniae), with limited activity against Gram-negative
organisms. It therefore seems unlikely that any beneficial
effect of macrolide therapy for stroke-associated infections
(including stroke-associated pneumonia) would be explained
on the basis of anti-microbial spectrum. However, macrolides
improve coverage of atypical organisms in community acquired
pneumonia (CAP), and have synergistic effects combined with
β lactam agents, which could be relevant in stroke-associated
pneumonia (28). Indeed, macrolides reduced in-patient
mortality rates in hospitalized, severe CAP when added to
β-lactam antibiotics (29).
Second, several antibiotic classes have immuno-modulatory
effects which could either facilitate host immune responses to
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FIGURE 1 | Forest plots illustrating the associations between antibiotic class and 90 day modified Rankin Scale (mRS), Barthel index (BI) and National Institutes of
Health Stroke Scale (NIHSS) score for any infection, using multifactorial ordinal logistic regression. CI indicates Confidence Interval.
bacterial challenge, or limit excessive inflammation in the lung.
Macrolides have a range of immuno-modulatory effects (30),
suppressing innate responses and inducing Th1 to Th2 shift.
In a mouse model of pneumococcal pneumonia, addition of
azithromycin to ceftriaxone induced specific changes in immune-
checkpoint ligands (e.g., up-regulation of CD86 and MHC II in
neutrophils and CD11b+CD11c+ macrophages) and receptors
(e.g., down-regulation of CTLA-4) in bronchoalveolar lavage
fluid, which may have contributed to the observed increased
survival (31).
Third, peripherally administered antibiotics could have
protective or deleterious effects on evolving cerebral infarction,
reparative processes, or both, particularly as they are frequently
prescribed within the first week after stroke onset. In
experimental stroke, in the absence of infection, macrolides
administered peripherally after middle cerebral artery occlusion
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FIGURE 2 | Forest plots illustrating the associations between antibiotic class and 90 day modified Rankin Scale (mRS), Barthel index (BI) and National Institutes of
Health Stroke Scale (NIHSS) score for pneumonia, using multifactorial ordinal logistic regression. CI, Confidence Interval.
are consistently protective; reducing infarct volume, blood
brain barrier damage, markers of oxidative stress, infiltration
of circulating immune cells and early neurological deficit
(12, 14, 32–34). By contrast, peripheral administration of third
generation cephalosporins in experimental stroke has revealed
conflicting findings in different studies (10, 35, 36). However,
in humans, cerebrospinal-fluid penetration of macrolides
and β-lactam antibiotics is generally poor, and highest for
fluoroquinolones and metronidazole (37).
CONCLUSION
In this retrospective analysis, treatment of any infection or
pneumonia within 2 weeks of stroke with macrolides was
independently associated with a favorable clinical outcome.
By contrast, treatment of any infection with cephalosporins,
carbapenems or monobactams; or penicillin plus β-lactamase,
was independently associated with unfavorable outcome.
Although there is a risk of residual confounding and bias,
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TABLE 8 | Multifactorial ordinal logistic regression for associations with worse 90
day BI.
Pneumonia (n = 751
patients)
Any infection (n = 2124
patients)
OR 95% CI p OR 95% CI p
Antibiotic class
Lincosamides and
tetracyclines
1.02 0.66 to 1.57 0.95 1.53 1.09 to 2.15 0.015
Cephalosporins,
carbapenems and
monobactams
1.36 0.99 to 1.87 0.05 1.70 1.39 to 2.07 <0.001
Aminoglycosides 1.09 0.63 to 1.88 0.75 1.69 1.17 to 2.44 0.005
Fluoroquinolones 1.11 0.81 to 1.53 0.54 1.27 1.04 to 1.55 0.02
Penicillins 1.05 0.66 to 1.67 0.84 1.19 0.90 to 1.57 0.23
Penicillin plus
β-lactamase inhibitor
1.00 0.73 to 1.37 0.98 1.30 1.05 to 1.61 0.02
Other* 1.26 0.67 to 2.36 0.47 1.53 1.24 to 1.89 <0.001
Macrolides 0.38 0.24 to 0.61 <0.001 0.50 0.35 to 0.72 <0.001
Sex
Female Ref Ref
Male 1.02 0.78 to 1.33 0.91 1.03 0.88 to 1.21 0.73
Increasing age (y) 1.05 1.04 to 1.06 <0.001 1.05 1.04 to 1.06 <0.001
Baseline NIHSS 1.11 1.08 to 1.14 <0.001 1.14 1.12 to 1.16 <0.001
Infection subtype
Pneumonia 1.52 1.12 to 2.07 0.007
Tracheobronchitis 0.79 0.53 to 1.17 0.24
Urogenital 0.65 0.49 to 0.88 0.005
Other 0.86 0.62 to 1.20 0.38
Uncertain 1.18 0.86 to 1.62 0.31
Treated with IV alteplase
No Ref
Yes 0.85 0.62 to 1.16 0.31 0.70 0.58 to 0.84 <0.001
Prior statin
No Ref
Yes 1.09 0.49 to 2.46 0.83 1.32 0.90 to 1.92 0.15
Unrecorded 1.38 0.78 to 2.47 0.27 1.17 0.84 to 1.61 0.35
Smoking status
Non-smoker Ref
Smoker 1.06 0.56 to 2.01 0.85 0.81 0.55 to 1.19 0.29
Unrecorded 1.09 0.47 to 2.52 0.84 0.98 0.61 to 1.58 0.94
Region
Australasia/Africa Ref
Asia 0.88 0.40 to 1.94 0.74 1.17 0.68 to 2.02 0.57
Europe 1.06 0.51 to 2.20 0.88 1.53 0.92 to 2.53 0.10
America 1.08 0.51 to 2.28 0.85 1.27 0.76 to 2.11 0.36
Increasing year of study 1.00 0.93 to 1.08 0.98 1.04 1.00 to 1.09 0.05
*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides
and nitrofurans.
BI, Barthel Index; OR, Odds ratio; CI, Confidence Interval; NIHSS, National Institutes of
Health Stroke Scale; IV, intravenous.
these data warrant further study in an appropriately designed
prospective study or controlled trial evaluation.
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TABLE 9 | Multifactorial ordinal logistic regression for associations with worse 90
day NIHSS.
Pneumonia
(n = 781 patients)
Any infection
(n = 2215 patients)
OR 95% CI P OR 95% CI p
Antibiotic class
Lincosamides and
tetracyclines
0.96 0.63 to 1.46 0.86 1.33 0.96 to 1.85 0.09
Cephalosporins,
carbapenems, and
monobactams
1.26 0.93 to 1.70 0.14 1.56 1.28 to 1.90 <0.001
Aminoglycosides 1.09 0.65 to 1.85 0.74 1.81 1.27 to 2.58 0.001
Fluoroquinolones 1.01 0.74 to 1.38 0.95 1.18 0.98 to 1.43 0.09
Penicillins 1.06 0.68 to 1.66 0.79 1.12 0.86 to 1.46 0.40
Penicillin plus
β-lactamase inhibitor
0.95 0.70 to 1.29 0.73 1.26 1.04 to 1.53 0.02
Other* 1.34 0.74 to 2.44 0.34 1.33 1.08 to 1.63 0.006
Macrolides 0.59 0.37 to 0.94 0.03 0.67 0.56 to 0.80 0.007
Sex
Female Ref Ref
Male 1.12 0.86 to 1.45 0.41 1.08 0.92 to 1.26 0.34
Increasing age (y) 1.04 1.02 to 1.05 <0.001 1.03 1.02 to 1.04 <0.001
Baseline NIHSS 1.14 1.11 to 1.18 <0.001 1.18 1.16 to 1.20 <0.001
Infection subtype
Pneumonia 1.57 1.17 to 2.11 0.003
Tracheobronchitis 0.95 0.65 to 1.38 0.78
Urogenital 0.68 0.51 to 0.91 0.008
Other 0.84 0.61 to 1.14 0.27
Uncertain 1.15 0.85 to 1.56 0.37
Treated with IV alteplase
No Ref
Yes 0.93 0.69 to 1.27 0.66 0.78 0.65 to 0.93 0.007
Prior statin
No Ref
Yes 1.06 0.56 to 2.00 0.87 1.00 0.73 to 1.38 0.99
Unrecorded 1.51 0.86 to 2.64 0.15 1.24 0.91 to 1.69 0.18
Smoking status
Non-smoker Ref
Smoker 1.17 0.63 to 2.20 0.62 1.08 0.74 to 1.56 0.70
Unrecorded 1.04 0.45 to 2.39 0.93 0.97 0.60 to 1.54 0.88
Region
Australasia/Africa Ref
Asia 1.19 0.55 to 2.59 0.66 1.59 0.95 to 2.64 0.08
Europe 0.97 0.47 to 2.01 0.94 1.18 0.73 to 1.90 0.51
America 1.05 0.50 to 2.22 0.90 1.16 0.71 to 1.90 0.54
Increasing year of study 0.96 0.90 to 1.04 0.32 0.99 0.95 to 1.03 0.57
*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides
and nitrofurans.
OR, Odds ratio; CI, Confidence Interval; NIHSS, National Institutes of Health Stroke Scale;
IV, intravenous.
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